CN116615458A - 抗cd73抗体的制剂 - Google Patents

抗cd73抗体的制剂 Download PDF

Info

Publication number
CN116615458A
CN116615458A CN202180079028.7A CN202180079028A CN116615458A CN 116615458 A CN116615458 A CN 116615458A CN 202180079028 A CN202180079028 A CN 202180079028A CN 116615458 A CN116615458 A CN 116615458A
Authority
CN
China
Prior art keywords
cancer
ser
composition
results
histidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180079028.7A
Other languages
English (en)
Chinese (zh)
Inventor
朱静
张哲如
朱祥平
于亚丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjing Biotechnology Shanghai Co ltd
Original Assignee
Tianjing Biotechnology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjing Biotechnology Shanghai Co ltd filed Critical Tianjing Biotechnology Shanghai Co ltd
Publication of CN116615458A publication Critical patent/CN116615458A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202180079028.7A 2020-12-30 2021-05-08 抗cd73抗体的制剂 Pending CN116615458A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/141601 2020-12-30
CN2020141601 2020-12-30
PCT/CN2021/092485 WO2022142053A1 (en) 2020-12-30 2021-05-08 Formulations of anti-cd73 antibodies

Publications (1)

Publication Number Publication Date
CN116615458A true CN116615458A (zh) 2023-08-18

Family

ID=82258959

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180079028.7A Pending CN116615458A (zh) 2020-12-30 2021-05-08 抗cd73抗体的制剂

Country Status (8)

Country Link
US (1) US20240101698A1 (https=)
EP (1) EP4271410A4 (https=)
JP (1) JP2024505128A (https=)
KR (1) KR20230127292A (https=)
CN (1) CN116615458A (https=)
AU (1) AU2021415180A1 (https=)
CA (1) CA3203441A1 (https=)
WO (1) WO2022142053A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119744177A (zh) * 2023-07-24 2025-04-01 石药集团巨石生物制药有限公司 重组人源化抗cd73单克隆抗体的药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109476755A (zh) * 2017-01-24 2019-03-15 天境生物 Cd73抗体及其用途
WO2020111913A1 (en) * 2018-11-30 2020-06-04 Abl Bio Inc. Anti-4-1bb antibody and use thereof
CN112004553A (zh) * 2018-04-25 2020-11-27 免疫医疗有限公司 人抗pd-l1抗体的配制品
CN112041348A (zh) * 2018-07-25 2020-12-04 天境生物科技(上海)有限公司 抗cd73抗pd-l1双特异性抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SV2007002227A (es) * 2004-09-10 2007-03-20 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
JP5933975B2 (ja) * 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
CN102413839A (zh) * 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
CN102512384B (zh) * 2011-12-29 2014-11-26 嘉和生物药业有限公司 一种冻干剂型蛋白组合物及其制备方法
MX2018003298A (es) * 2015-09-22 2018-06-20 Pfizer Metodo para preparar una formulacion de proteinas terapeuticas y formulacion de anticuerpos producida por tal metodo.
WO2017189433A1 (en) * 2016-04-25 2017-11-02 Medimmune, Llc Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
CN111686247B (zh) * 2019-03-13 2022-07-29 苏州康乃德生物医药有限公司 包含人白介素-4受体α的抗体的液体组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109476755A (zh) * 2017-01-24 2019-03-15 天境生物 Cd73抗体及其用途
CN112004553A (zh) * 2018-04-25 2020-11-27 免疫医疗有限公司 人抗pd-l1抗体的配制品
CN112041348A (zh) * 2018-07-25 2020-12-04 天境生物科技(上海)有限公司 抗cd73抗pd-l1双特异性抗体
WO2020111913A1 (en) * 2018-11-30 2020-06-04 Abl Bio Inc. Anti-4-1bb antibody and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
吴晓丽: "抗体A的制剂处方研究", 食品与发酵科技, vol. 53, no. 1, 25 February 2017 (2017-02-25) *
邱晓: "重组单克隆抗体药物制剂处方的作用及相关审评要点", 中国新药杂志, vol. 28, no. 16, 30 August 2019 (2019-08-30), pages 1947 - 1954 *

Also Published As

Publication number Publication date
WO2022142053A1 (en) 2022-07-07
EP4271410A1 (en) 2023-11-08
AU2021415180A1 (en) 2023-07-06
CA3203441A1 (en) 2022-07-07
KR20230127292A (ko) 2023-08-31
JP2024505128A (ja) 2024-02-05
EP4271410A4 (en) 2025-08-13
US20240101698A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
KR102847571B1 (ko) 프로그램화된 사멸 수용체 1 (pd-1) 항체의 안정한 제제 및 그의 사용 방법
CN110678199B (zh) 单独的和与程序性死亡受体1(pd-1)抗体组合的抗ctla4抗体的稳定制剂及其使用方法
US20260000604A1 (en) Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof
KR20160079890A (ko) 항체-약물 접합체 동결건조 제제
JP7805289B2 (ja) 抗コネキシン抗体製剤
CN112516090B (zh) 抗体偶联药物的药物组合、冷冻干燥剂及制备方法、用途
WO2022128716A1 (en) Pharmaceutical composition comprising a bispecific anti-muc1/egfr antibody-drug conjugate
EP4374874A1 (en) Pharmaceutical composition containing anti-trop2 antibody drug conjugate and use thereof
CA3252354A1 (en) Pharmaceutical composition containing an anti-nectin-4 antibody conjugate and its use
CN119971023A (zh) 含抗lag-3抗体的药物组合物及其用途
CN116615458A (zh) 抗cd73抗体的制剂
WO2015059147A1 (en) A novel stable formulation
KR20240024941A (ko) 항-pd1 항체의 제제
TWI880260B (zh) 抗pd-l1/抗-4-1bb雙特異性抗體製劑
JP2024526920A (ja) 骨標的療法のための操作された組成物
CN113842467A (zh) 用于抗体与药物偶联体（adc）制备的中间体及其制备方法和应用
EP4403575A1 (en) Composition comprising pd-l1 antigen-binding fragment and use thereof
KR20260058842A (ko) 항-psma adc 접합체 조성물 및 이의 사용 방법
EA052347B1 (ru) Композиция, содержащая фрагмент, связывающий антиген pd-l1, и ее применение
AU2024329469A1 (en) Anti-psma adc conjugate compositions and methods of use thereof
HK40077586A (en) Anto-connexin antibody formulations
EP4548931A1 (en) Anti-pcsk9 antibody preparation and use thereof
CN118542950A (zh) 抗cldn-18.2抗体药物偶联物药物组合物及其用途
HK1215796A1 (en) Anti her2 antibody formulation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination